- Press releases
- Country: United States
Mentara Therapeutics Launches to Advance MTA-304, a Phase 2-Ready PDE10A Inhibitor, for Levodopa-Induced Dyskinesia in Parkinson's Disease
-SPRIM Global Investments-backed company acquires asset from EuMentis Therapeutics- - Phase 2 study planned for first half of 2027- SAN DIEGO and SYDNEY, Oct. 7, 2026 /PRNewswire/ -- Mentara Therapeutics, a new neuropsychiatry company backed by SPRIM Global Investments, today launched...